Aurinia Pharmaceuticals Inc $AUPH Stock Bought by Ritholtz Wealth Management

Ritholtz Wealth Management boosted its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 11.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 405,562 shares of the biotechnology company’s stock after purchasing an additional 42,506 shares during the period. Ritholtz Wealth Management owned about 0.30% of Aurinia Pharmaceuticals worth $6,568,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. BlackRock Inc. purchased a new stake in Aurinia Pharmaceuticals in the second quarter worth $139,037,000. Renaissance Technologies LLC raised its stake in shares of Aurinia Pharmaceuticals by 4.6% in the first quarter. Renaissance Technologies LLC now owns 1,663,835 shares of the biotechnology company’s stock valued at $24,658,000 after buying an additional 73,700 shares during the period. Allianz Asset Management GmbH purchased a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter valued at $14,284,000. Janus Henderson Group PLC lifted its position in shares of Aurinia Pharmaceuticals by 9.7% during the 1st quarter. Janus Henderson Group PLC now owns 757,435 shares of the biotechnology company’s stock valued at $11,225,000 after buying an additional 66,806 shares during the last quarter. Finally, Jupiter Topco LLC purchased a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter valued at $10,219,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Zacks Research lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Wall Street Zen downgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Royal Bank Of Canada upped their price objective on shares of Aurinia Pharmaceuticals from $16.00 to $18.00 and gave the company a “sector perform” rating in a report on Monday, November 2nd. Bloom Burton upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Finally, TD Cowen lifted their target price on shares of Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.33.

Aurinia Pharmaceuticals Price Performance

Shares of Aurinia Pharmaceuticals stock opened at $16.21 on Friday. The company has a current ratio of 6.12, a quick ratio of 5.67 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $2.17 billion, a PE ratio of 15.89 and a beta of 1.40. The business’s 50-day moving average price is $16.49 and its 200-day moving average price is $15.72. Aurinia Pharmaceuticals Inc has a 12 month low of $13.52 and a 12 month high of $19.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Friday, October 30th. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.22 by $0.01. The firm had revenue of $83.70 million for the quarter, compared to the consensus estimate of $83.61 million. Aurinia Pharmaceuticals had a net margin of 97.68% and a return on equity of 22.99%. Sell-side analysts forecast that Aurinia Pharmaceuticals Inc will post 0.97 EPS for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.